The company has a one year high of $9.08 and a one year low of $1.19. Currently, Marinus has an average volume of 217.8K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $3.00, reflecting a -55.7% downside.
Over the last 3 months, the insider sentiment on Marinus has been negative based on 11 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of neuropsychiatric therapeutics. Its clinical stage drug candidate, ganaxolone, is a novel synthetic small molecule that is an analog of allopregnanolone, a natural occurring neurosteriod produced by the human body, which modulates gamma-aminobutyric acid a neurotransmitter in the brain. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.